Celldex Therapeutics’ (CLDX) “Buy” Rating Reaffirmed at Cantor Fitzgerald

Celldex Therapeutics Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report issued on Monday. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 117.39% from the company’s current price.

The analysts wrote, “Celldex Receives a Buy from Cantor Fitzgerald | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘http://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=ae16fd92b5&wpp_id=456014’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
/* Send request */
xhr.send( params );


(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;


Stock Market
Best Performing Analysts

Basic Materials
Consumer Goods
Industrial Goods

Most Popular
Contact Us

Home » Celldex Receives a Buy from Cantor Fitzgerald”

Several other research analysts have also recently commented on CLDX. Wedbush reiterated a “neutral” rating and issued a $3.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Jefferies Group reiterated a “hold” rating and issued a $5.00 price target (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Finally, Brean Capital assumed coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They issued a “buy” rating and a $16.00 price target on the stock. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $7.75.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up 0.72% on Monday, hitting $4.17. The company’s stock had a trading volume of 949,691 shares. The firm’s market cap is $419.27 million. The company has a 50 day moving average of $3.75 and a 200 day moving average of $4.17. Celldex Therapeutics has a 1-year low of $2.96 and a 1-year high of $18.62.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The business had revenue of $1.39 million for the quarter, compared to analysts’ expectations of $0.96 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The company’s revenue was down 36.4% compared to the same quarter last year. Equities analysts forecast that Celldex Therapeutics will post ($1.34) EPS for the current year.

Several institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Celldex Therapeutics by 4.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 373,066 shares of the biopharmaceutical company’s stock valued at $1,638,000 after buying an additional 14,300 shares during the period. Alps Advisors Inc. raised its position in Celldex Therapeutics by 24.9% in the second quarter. Alps Advisors Inc. now owns 138,680 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 27,677 shares during the period. Bank of Montreal Can bought a new position in Celldex Therapeutics during the second quarter valued at approximately $188,000. Marcus Capital LLC raised its position in Celldex Therapeutics by 58.5% in the second quarter. Marcus Capital LLC now owns 111,600 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 41,200 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in Celldex Therapeutics by 2.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,903 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 1,412 shares during the period. 78.41% of the stock is owned by institutional investors.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

5 Day Chart for NASDAQ:CLDX

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.